Derivatives of pentamidine designed to target the Leishmania lipophosphoglycan

Tetrahedron Letters

Volumn 46, Issue 4, 2005, Pages 695-698

  Kramp, Kari L ^a   DeWitt, Kristin ^b   Flora, Jason W ^a   Muddiman, David C ^a   Slunt, Kelli M ^b   Houston, Todd A ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MARY WASHINGTON   (United States)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Boronate drug targeting; Leishmania; Pentamidine

Indexed keywords

LIPOPHOSPHOGLYCAN; PENTAMIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG BINDING; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; LEISHMANIA;

PROTOZOA;

EID: 11144321488     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2004.11.112     Document Type: Article

References (32)

1. S.J. Turco, and A. Descoteaux Annu. Rev. Microbiol. 46 1992 65 94
2. D.L. Sacks Exp. Parasitol. 69 1989 100 103
3. D.L. Sacks, G. Modi, E. Rowton, G. Späth, L. Epstein, S.J. Turco, and S.M. Beverley PNAS 97 2000 406 411
4. A. Meyerhoff Clin. Infect. Dis. 28 1999 42 48
5. A. Cascio, L. di Martino, P. Occorsio, R. Giacchino, S. Catania, A.R. Gigliotti, C. Aiassa, C. Iaria, S. Giordano, C. Colomba, V.F. Polara, L. Titone, L. Gradoni, M. Gramiccia, and S. Antinori J. Antimicrob. Chemother. 54 2004 217 220
6. R.R.C. New, M.L. Chance, S.C. Thomas, and W. Peters Nature (London) 272 1978 55 57
7. A.G. Tempone, D. Perez, S. Rath, A.L. Vilharinho, R.A. Mortara, and H.F. de Andrade J. Antimicrob. Chemother. 54 2004 60 68
8. A. Mukhopadhyay, G. Chaudhuri, S.K. Arora, S. Sehgal, and S.K. Basu Science (Washington, DC) 244 1989 705 707
9. R. Durand, M. Paul, D. Rivollet, R. Houin, A. Astier, and M. Deniau Int. J. Parasitol. 27 1997 1361 1367
10. O. Kayser Int. J. Pharm. 196 2000 253 256
11. A. Nan, S.L. Croft, V. Yardley, and H. Ghandehari J. Controlled Release 94 2004 115 127
12. M.J. McConville, J.E. Thomas-Oates, M.A.J. Ferguson, and S.W. Homans J. Biol. Chem. 265 1990 19611 19623
13. A. Descoteaux, Y. Luo, S.J. Turco, and S.M. Beverley Science (Washington, DC) 269 1995 1869 1872
14. G.F. Späth, L. Epstein, B. Leader, S.M. Singer, H.A. Avila, S.J. Turco, and S.M. Beverley PNAS 97 2000 9258 9263
15. G. Springsteen, and B. Wang Tetrahedron 58 2002 5291 5300
16. C.W. Gray Jr., B.T. Walker, R.A. Foley, and T.A. Houston Tetrahedron Lett. 44 2003 3309 3312
17. L.L. Johnson Jr., and T.A. Houston Tetrahedron Lett. 43 2002 8905 8908
18. W. Yang, S. Gao, X. Gao, V.V.R. Karnati, W. Ni, B. Wang, W.B. Hooks, J. Carson, and B. Weston Bioorg. Med. Chem. Lett. 12 2002 2175 2177
19. J.N. Ashley, H.J. Barber, A.J. Ewins, G. Newbery, and A.D.H. Self J. Chem. Soc. 1942 103 116
20. P.G. Bray, M.P. Barrett, S.A. Ward, and H.P. de Koning Trends Parisitol. 19 2003 232 239
21. D. Henderson, and L.H. Hurley Nature Med. 1 1995 525 527
22. L.E. Burgess, B.J. Newhouse, P. Ibrahim, J. Rizzi, M.A. Kashem, A. Hartman, B.J. Brandhuber, C.D. Wright, D.S. Thomson, G.P.A. Vigers, and K. Koch PNAS 96 1999 8348 8352
23. H.A. Johnson, and N.R. Thomas Bioorg. Med. Chem. Lett. 12 2002 237 241
24. I.O. Donkor, T.L. Huang, B. Tao, D. Rattendi, S. Lane, M. Vargas, B. Goldberg, and C. Bacchi J. Med. Chem. 46 2003 1041 1048
25. C.E. Stephens, R. Brun, M.M. Salem, K.A. Werbovetz, F. Tanious, W.D. Wilson, and D.W. Boykin Bioorg. Med. Chem. Lett. 13 2003 2065 2069
26. K.M. Slunt, J.M. Grace, T.L. MacDonald, and R.D. Pearson Antimicrob. Agents Chemother. 40 1996 706 709
27. 3
28. C.W. Gray Jr., and T.A. Houston J. Org. Chem. 67 2002 5426 5428
29. Compounds 2-7 were tested for leishmanicidal activity against the L. chagasi strain as follows. A 10 mM stock solution for each of the eight trials (six compounds in DMSO, pentamidine (1) in DMSO, and a DMSO control) were prepared. Each drug was diluted to a concentration of 400 μM with modified HOMEM buffer system. Addition of 40 μL DMSO in 460 μL HOMEM served as a solvent control. Initially, 100 μL of HOMEM was placed in all 12 rows of 8 columns of an 8 × 12 sterile cell well plate (FALCON 3872). Duplicate serial dilutions of each drug were made as follows: 100 μL of the 400 μM drug solution was pipetted into wells 1 and 2 (rows 1 and 2), 100 μL of the solution in well 1 was pipetted into well 3, and 100 μL of the solution in well 2 was pipetted into well 4. This procedure was repeated until 100 μL was removed from wells 11 and 12 at the end. To each well 100 μL of L. chagasi promastigotes at approximately 5 × 106 parasites/mL was added, and the cell well plate was placed in an incubator at 25°C overnight. The parasites were counted after 24 and 48 h incubation time by pipetting 10 μL of solution from each well under the cover slip of a hemacytometer with a 5 × 5 major grid divided into 4 × 4 minor grids. The number of parasites in two major grids was counted (viewed at 400× magnification), averaged, and converted to parasites/mg by multiplying by 25 × 104. The average parasite counts were converted into percent parasite fatality as shown in Table 1
30. S.J. Gardiner, B.D. Smith, P.J. Duggan, M.J. Karpa, and G.J. Griffin Tetrahedron 55 1999 2857 2864
31. S.P. Draffin, P.J. Duggan, and S.A.M. Duggan Org. Lett. 3 2001 917 920
32. B.D. Smith, J.P. Davis, S.P. Draffin, and P.J. Duggan Supramol. Chem. 16 2004 87 90